Home › NDC Lookup › RxCUI directory › RxCUI 2712644

Ensartinib 25 MG Oral Capsule [Ensacove] — RxCUI 2712644

RxNorm drug concept · Semantic branded drug
RxCUI 2712644 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2712644
Official nameEnsartinib 25 MG Oral Capsule [Ensacove]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asEnsacove 25 MG (as ensartinib hydrochloride 28.25 MG) Oral Capsule; Ensacove 25 MG Oral Capsule
FDA products mapped2
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Ensartinib 25 MG Oral Capsule [Ensacove] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Ensartinib 25 MG Oral Capsule [Ensacove] RxCUI 2712644

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Ensartinib 2712546
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Ensacove 2712635
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Ensartinib Oral Capsule 2712633
    • Ensartinib Oral Product 2712631
    • Ensartinib Pill 2712632
    • Ensartinib Oral Capsule [Ensacove] 2712639
    • Ensacove Oral Product 2712637
    • Ensacove Pill 2712638
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Ensartinib 25 MG Oral Capsule SCD · 2712642
  • Ensartinib 25 MG SCDC · 2712641
  • Ensartinib Oral Capsule SCDF · 2712633
  • Ensartinib Oral Product SCDG · 2712631
  • Ensartinib Pill SCDG · 2712632

Brand-Name Concepts

  • Ensartinib 25 MG [Ensacove] SBDC · 2712643
  • Ensartinib Oral Capsule [Ensacove] SBDF · 2712639
  • Ensacove Oral Product SBDG · 2712637
  • Ensacove Pill SBDG · 2712638
  • Ensacove BN · 2712635

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2712644 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
83076-1025-03 30 CAPSULE in 1 BOTTLE (83076-1025-3) ENSACOVE Xcovery Holdings, Inc. 2025-04-30
83076-1100-06 60 CAPSULE in 1 BOTTLE (83076-1100-6) ENSACOVE Xcovery Holdings, Inc. 2025-04-30
Observed labelers: Xcovery Holdings, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.